Gene · 369
NIH grants1,471
NIH grants whose papers are about the gene, through NIH's grant-paper links.
561 to 580 of 1,471
Download this page as JSON| Grant | Title | ARAF papers | Newest fiscal year |
|---|---|---|---|
| R50CA243885 | Functional Cancer Cell Maps | 1 | 2021 |
| T32CA124334 | Cancer Biology Training Grant | 1 | 2021 |
| T32GM007171 | Medical Scientist Training Program | 1 | 2021 |
| T32GM007175 | Pharmaceutical Sciences and Pharmacogenomics | 1 | 2021 |
| T32GM007445 | Biochemistry, Cellular and Molecular Biology Program | 1 | 2021 |
| T32GM119999 | Training in Mechanistic, Interdisciplinary Studies of Biological Systems | 1 | 2021 |
| U01CA200469 | Development of in vitro diagnostic multivariate index assay using liquid-based cervical cytology specimen and/or serum/plasma biomarkers for the detection of early stage or low-volume ovarian cancer | 1 | 2021 |
| U01CA206997 | Imaging of nanotherapeutic drug action | 1 | 2021 |
| U01CA213333 | Targeting the transcriptional and epigenetic landscape in chemo-refractory Small-Cell Lung Cancer | 1 | 2021 |
| U01CA214114 | Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit | 1 | 2021 |
| U01CA214170 | Discovery and qualification of transcriptomic biomarkers for the early detection of aggressive prostate cancer | 1 | 2021 |
| U01CA217078 | Development of 5hmC and 5mC biomarkers in cell-free circulating DNA for sensitive colon cancer detection and prognosis | 1 | 2021 |
| U01CA217842 | Integrative bioinformatics and functional characterization of oncogenic driver aberrations in cancer | 1 | 2021 |
| U01CA217882 | The Cancer Target Discovery and Development Network at UCSF | 1 | 2021 |
| U19AI131130 | Engineering a human brain organoid-based platform to study neurotropic viruses | 1 | 2021 |
| U24CA184427 | NDEx - the Network Data Exchange A Network Commons for Biologists | 1 | 2021 |
| U54CA156735 | NCCU-LCCC Partnership in Cancer Research | 1 | 2021 |
| U54CA217377 | Quantitative and functional characterization of therapeutic resistance in cancer | 1 | 2021 |
| ZIABC011438 | Genetic screens for target discovery in cancer | 1 | 2021 |
| ZIABC011805 | Defining the Mechanism of Action of Rigosertib in Pediatric Cancers | 1 | 2021 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/369/grants?page=29